XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses    
Research and development $ 30,312,000 $ 27,080,000
General and administrative 12,688,000 12,700,000
Goodwill impairment 0 48,648,000
Total operating expenses 43,000,000 88,428,000
Other income, net 2,674,000 462,000
Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds (76,211,000)  
Net loss and comprehensive loss $ (116,537,000) $ (87,966,000)
Net loss per share, basic $ (4.73) $ (6.16)
Net loss per share, diluted $ (4.73) $ (6.16)
Weighted-average common shares outstanding, basic 24,619,197 14,285,254
Weighted-average common shares outstanding, diluted 24,619,197 14,285,254